Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Down 5.68%
As of Wednesday, July 29, Gyre Therapeutics, Inc.’s GYRE share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Commentary & Analysis
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.22%
As of Monday, July 27, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 5.06%
As of Thursday, July 02, Gyre Therapeutics, Inc.’s GYRE share price has surged by 5.06%, which has investors questioning if this is right time to sell.Michael Rose
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 6.20%
As of Wednesday, June 24, Gyre Therapeutics, Inc.’s GYRE share price has surged by 6.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Gyre Therapeutics, Inc.’s (GYRE) Stock Is Up 7.21%
As of Thursday, June 04, Gyre Therapeutics, Inc.’s GYRE share price has surged by 7.21%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $641.1 | $252.6 | 40% |
|
| Shares Out (Mil) | 91.3 | 52.3 | 60% |
|
| Institutional Ownership | 36.0% | 92.1% | 16% |
|
| Float (Mil) | 41.4 | 40.2 | 43% |
|
| Beta | 4.77 | 0.95 | 99% |
|
| Avg Daily Volume (000s) | 48 | 455 | 28% |
|
| Price Change (52-week) |
(20.9%) | 52.9% | 30% |
|
| Growth | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.073) | ($0.290) | ($0.115) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 2 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (24.0%) | (1,418%) | 8,491% | |
| Financials | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $38 | 28% |
|
| Net Income (TTM) (Mil) | ($6) | ($43) | 32% |
|
| EPS (TTM) | ($0.070) | ($1.600) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | $4 | ($31) | 35% |
|
| Net Cash Flow (TTM) (Mil) | $23 | $5 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 10% |
|
| Enterprise Value (Q1) (Mil) | $589 | $180 | 36% |
|
| Valuation | GYRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.18 | 2.56 | 79% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GYRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 95.1% | 63.8% | 95% |
|
| Net Margin | (5.4%) | (67.3%) | 25% |
|
| ROA | (4.4%) | (49.8%) | 31% |
|
| ROE | (7.5%) | (55.5%) | 29% |
|
| Liabilities to Assets | 15.4% | 30.3% | 9% |
|
| F-Score | 5 | 3 | 51% |
|
Gyre Therapeutics, Inc. did not pass any screens on 7/31/2026.
